Business
Alloy Therapeutics Enters Into Agreement to Advance Novel Antibody Discovery Platform
BOSTON, March 17, 2026--Alloy Therapeutics, Inc. ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced an agreement with AbbVie to develop a new antibody platform to discover potent, specific, and effective antibodies against targets that are difficult to address with current technologies. As part of the multi-year agreement, Alloy will receive an upfront payment, as well as an additional payment in connection
About this update from Abbvie Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1920,"height":645,"url":"https://media.zenfs.com/en/business-wire.com/5bf458022c94309efa2fbd286df7a078"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_rE6BmVchRbZrIAxyquOUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyMztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5bf458022c94309efa2fbd286df7a078","width":960,"height":323},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/pZQfaYMVfItxZMD0Yfc7AA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MDY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/5bf458022c94309efa2fbd286df7a078","width":1200,"height":403}},"lazy":false},{"type":"text","content":"BOSTON, March 17, 2026--(BUSINESS WIRE)--Alloy Therapeutics, Inc. ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced an agreement with AbbVie to develop a new antibody platform to discover potent, specific, and effective antibodies against targets that are difficult to address with current technologies. As part of the multi-year agreement, Alloy will receive an upfront payment, as well as an additional payment in connection with the delivery of the platform to AbbVie.","length":571,"tagName":"p"},{"type":"text","content":"The collaboration provides AbbVie with access to the antibody discovery platform as part of its broader research efforts. For Alloy, the collaboration reflects its continued focus on enabling partners through platform-based discovery technologies and reinforces its commitment to advancing antibody therapeutics.","length":312,"tagName":"p"},{"type":"text","content":"Alloy’s ATX-Gx platform has rapidly become the industry standard for fully humanized transgenic mice, and is now used by over 200 partners to enable many therapeutic discovery programs. Alloy is dedicated to reinvesting its revenue into innovation and has continuously expanded its platform offerings, developing new strains and tools to meet the evolving needs of antibody discovery. This commitment ensures Alloy remains at the forefront of enabling partners to access advanced technologies that accelerate drug development.","length":526,"tagName":"p"},{"type":"text","content":""We believe the best technologies are built ...